Zepbound is a weekly injection for chronic weight management. The medication is available in six doses through prescriptions that can be filled by retail or mail-order pharmacies, Eli Lilly said in a Dec. 5 news release.
The drug shares a main ingredient, tirzepatide, with Eli Lilly’s type 2 diabetes treatment Mounjaro, which has been widely prescribed off-label for weight loss.
On Nov. 8, the FDA approved Zepbound for obese or overweight adults who have at least one weight-related condition, such as high blood pressure or Type 2 diabetes. The drug is intended to be used alongside a reduced-calorie diet and increased physical activity.
Learn more about Zepbound here.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
